AVTR vs. TAK: Avantor vs. Takeda Pharmaceutical Stock Comparison

Company Profile

Avantor (AVTR) and Takeda Pharmaceutical (TAK) both fall under the Pharmaceuticals, Biotechnology & Life Sciences industry group, but AVTR is classified in Life Sciences Tools & Services while TAK is classified in Pharmaceuticals.

Avantor (AVTR) trades as ordinary local shares, while Takeda Pharmaceutical (TAK) trades as an ADR — compare with FX exposure, depositary-program fees, and dividend-withholding-tax differences in mind.

Price Performance

Cumulative Growth

Trailing Returns

Calendar-Year Returns

Performance Metrics

Risk Profile

Drawdown History

Return Distribution

Risk Metrics

Takeda Pharmaceutical (TAK) reports a negative beta of -0.01, suggesting inverse market sensitivity over the measurement window. That is uncommon for ordinary equities and can reflect commodity-linked or hedge-like exposure, but it can also come from statistical noise. Avantor (AVTR) has a non-negative beta of 0.94.

Risk-Adjusted Performance

Risk-Return Positioning

Risk-Adjusted Metrics

Profitability

Both Avantor (AVTR) at 5.91% and Takeda Pharmaceutical (TAK) at 0.56% land near their industries’ usual ROE ranges, so capital efficiency looks broadly in line with peers on both sides.

Avantor (AVTR) at 5.08% retains a top-quartile share of revenue as profit, ahead of Takeda Pharmaceutical (TAK) at 0.87%, which keeps about the industry-typical share.

Takeda Pharmaceutical (TAK) at 24.55% operates in the top operating margin quartile, ahead of Avantor (AVTR) at 8.19%, which runs around its industry’s norm.

Profitability Metrics

Growth

Both Avantor (AVTR) at -3.41% and Takeda Pharmaceutical (TAK) at -1.66% post bottom-quartile revenue growth versus peers, pointing to weaker demand or pricing momentum than typical rivals.

Takeda Pharmaceutical (TAK) at 77.96% sits in the top EPS growth quartile, while Avantor (AVTR) at -175.00% is in the bottom quartile, showing a clear gap in earnings momentum.

Growth Metrics

Financial Strength

Both Avantor (AVTR) at 1.89 and Takeda Pharmaceutical (TAK) at 1.15 run current ratio in the tighter-liquidity quartile of industry peers, leaving thinner cushions against current liabilities than typical competitors.

Avantor (AVTR) at 0.63 carries an industry-typical debt-to-equity mix, while Takeda Pharmaceutical (TAK) at 0.72 uses more debt funding than most peers.

Financial Strength Metrics

Dividends

Avantor (AVTR) pays no dividend (yield 0.00%) — it may be reinvesting, using buybacks, or simply not returning cash through dividends. Meanwhile Takeda Pharmaceutical (TAK) reports a yield of 953.28%, ranking against industry peers normally.

Takeda Pharmaceutical (TAK) reports payout ratio above 100% at 426.53%, meaning dividends exceeded current-period earnings; Avantor (AVTR) pays no dividend (payout 0.00%).

Dividend Metrics

Valuation

Avantor (AVTR) at 30.94 is near its industry’s usual P/E ratio, while Takeda Pharmaceutical (TAK) at 300.29 sits above its peer range — an unusually expensive price for TAK’s trailing earnings.

Both Avantor (AVTR) at 1.58 and Takeda Pharmaceutical (TAK) at 0.01 fetch a relatively low price per dollar of sales, landing in the cheaper P/S ratio quartile of their industries.

Takeda Pharmaceutical (TAK) at 1.43 sits in the lower P/B ratio quartile against book while Avantor (AVTR) at 1.80 is valued near its industry’s middle — TAK is cheaper on assets, though weigh it against ROE and asset quality.

Valuation Metrics